HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sandrine Faivre Selected Research

N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamide

1/2021Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
1/2021Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sandrine Faivre Research Topics

Disease

83Neoplasms (Cancer)
01/2022 - 04/2002
24Hepatocellular Carcinoma (Hepatoma)
08/2021 - 08/2009
11Squamous Cell Carcinoma of Head and Neck
01/2019 - 07/2004
10Renal Cell Carcinoma (Grawitz Tumor)
06/2016 - 01/2006
10Neoplasm Metastasis (Metastasis)
09/2014 - 04/2002
9Neuroendocrine Tumors (Neuroendocrine Tumor)
12/2014 - 12/2009
7Head and Neck Neoplasms (Head and Neck Cancer)
01/2019 - 04/2005
6Disease Progression
01/2017 - 06/2007
5Asthenia
01/2021 - 11/2005
5Neutropenia
01/2019 - 03/2008
5Carcinoma (Carcinomatosis)
01/2018 - 04/2009
5Carcinogenesis
01/2017 - 08/2010
5Colonic Neoplasms (Colon Cancer)
05/2010 - 04/2002
4Fatigue
01/2021 - 01/2009
4Diarrhea
01/2021 - 11/2005
4Necrosis
01/2017 - 05/2010
3Melanoma (Melanoma, Malignant)
01/2021 - 08/2007
3Primitive Neuroectodermal Tumors (PNET)
01/2018 - 09/2012
3Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
12/2014 - 06/2007
3Breast Neoplasms (Breast Cancer)
12/2013 - 08/2005
3Liver Diseases (Liver Disease)
10/2013 - 03/2007
3Hypertension (High Blood Pressure)
06/2012 - 06/2007
3Kidney Neoplasms (Kidney Cancer)
02/2012 - 06/2004
3Colorectal Neoplasms (Colorectal Cancer)
10/2010 - 08/2005
2Vomiting
12/2019 - 11/2005
2Nausea
12/2019 - 11/2005
2Stomach Neoplasms (Stomach Cancer)
10/2017 - 08/2005
2Biliary Tract Neoplasms (Biliary Tract Cancer)
09/2016 - 07/2014
2Peripheral Nervous System Diseases (PNS Diseases)
07/2014 - 03/2008
2Prostatic Neoplasms (Prostate Cancer)
12/2013 - 10/2007
2Glioblastoma (Glioblastoma Multiforme)
12/2013 - 07/2007
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2012 - 09/2011
2Adenocarcinoma
04/2012 - 08/2005
2Carcinoid Tumor (Carcinoid)
12/2010 - 12/2009
2Thyroid Neoplasms (Thyroid Cancer)
04/2010 - 10/2007
2Thrombocytopenia (Thrombopenia)
04/2009 - 05/2004
2Stomatitis
04/2009 - 06/2004

Drug/Important Bio-Agent (IBA)

23Sunitinib (Sutent)FDA Link
01/2018 - 01/2006
15Sorafenib (BAY 43-9006)FDA Link
08/2021 - 07/2010
11Pharmaceutical PreparationsIBA
01/2021 - 06/2004
9Biomarkers (Surrogate Marker)IBA
01/2020 - 07/2011
9PlatinumIBA
01/2019 - 05/2002
9EverolimusFDA Link
06/2016 - 04/2008
8Antineoplastic Agents (Antineoplastics)IBA
01/2017 - 08/2006
8TOR Serine-Threonine KinasesIBA
01/2017 - 06/2004
7Phosphotransferases (Kinase)IBA
01/2019 - 08/2006
6Proteins (Proteins, Gene)FDA Link
01/2020 - 05/2011
6GemcitabineFDA Link
09/2016 - 09/2011
6Oxaliplatin (Eloxatin)FDA LinkGeneric
04/2015 - 08/2002
6Imatinib Mesylate (Gleevec)FDA Link
12/2014 - 09/2005
6Fluorouracil (Carac)FDA LinkGeneric
07/2013 - 08/2002
6Irinotecan (Camptosar)FDA LinkGeneric
03/2008 - 08/2002
5Cetuximab (Erbitux)FDA Link
01/2019 - 08/2005
5Cisplatin (Platino)FDA LinkGeneric
07/2014 - 07/2006
5Monoclonal AntibodiesIBA
07/2013 - 08/2007
5temsirolimusFDA Link
05/2013 - 06/2004
5MTOR InhibitorsIBA
05/2013 - 01/2006
4LY-2157299IBA
01/2021 - 08/2015
4Transforming Growth Factor beta (TGF-beta)IBA
01/2020 - 05/2010
4Paclitaxel (Taxol)FDA LinkGeneric
01/2018 - 07/2008
4Messenger RNA (mRNA)IBA
12/2013 - 05/2010
4Sirolimus (Rapamycin)FDA Link
05/2013 - 01/2006
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2012 - 12/2009
4Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
06/2012 - 08/2005
4Protein Kinase CIBA
05/2010 - 08/2006
3tepotinibIBA
08/2021 - 01/2018
3Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2017 - 04/2008
3Tyrosine Kinase InhibitorsIBA
12/2014 - 01/2006
3VimentinIBA
12/2012 - 05/2010
3Mitogen-Activated Protein KinasesIBA
04/2012 - 08/2006
3Cytotoxins (Cytolysins)IBA
04/2008 - 05/2004
3irofulvenIBA
10/2007 - 05/2004
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021 - 02/2014
2N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA
01/2021 - 01/2021
2Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
01/2021 - 08/2006
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2021 - 02/2014
2BilirubinIBA
01/2019 - 11/2002
2antineoplaston A10 (A 10)IBA
01/2018 - 07/2011
2NVP-BKM120IBA
01/2018 - 01/2017
2LigandsIBA
11/2017 - 12/2012
2Cyclin D1IBA
01/2017 - 06/2011
2Hormones (Hormone)IBA
12/2014 - 10/2007
2Galectin 1 (LGALS1)IBA
09/2014 - 03/2014
2Transaminases (Aminotransferases)IBA
07/2014 - 11/2005
2elisidepsinIBA
06/2014 - 03/2013
2Carboplatin (JM8)FDA LinkGeneric
06/2014 - 07/2008
2ChemokinesIBA
01/2014 - 12/2013
2Angiogenesis InhibitorsIBA
09/2012 - 11/2008
2ErbB Receptors (EGF Receptor)IBA
09/2011 - 11/2007
2Cadherins (E-Cadherin)IBA
05/2011 - 05/2010
2CreatinineIBA
12/2010 - 04/2009
2plitidepsin (aplidine)IBA
04/2010 - 11/2005
23-ingenyl angelateIBA
05/2009 - 04/2008

Therapy/Procedure

36Therapeutics
01/2020 - 08/2006
18Drug Therapy (Chemotherapy)
01/2018 - 05/2002
5Radiotherapy
04/2009 - 05/2004
4Induction Chemotherapy
09/2014 - 04/2005
2Immunotherapy
01/2019 - 11/2007
2Hepatectomy
11/2012 - 06/2009
2Drug Tapering
01/2009 - 03/2007